Method for detecting mild cognitive impairment and mild alzheimer's disease
AssigneeThe University of Tokyo
InventorsYoshiya ODA, Suzumi TOKUOKA, Fumie HAMANO
Life of this patent
Estimating the term…
Abstract
A method for detecting mild cognitive impairment and/or mild Alzheimer's disease, includes measuring the amount or concentration of a biomolecule in a biological sample from a test subject. The biomolecule is one or more proteins selected from FGF-19, PLA2G10 and CPA2. In the detection method, it is possible to determine the likelihood of suffering from mild cognitive impairment and/or mild Alzheimer's disease using the amount or concentration of the biomolecule in the biological sample from the test subject as an index.
Claims25
A method for detecting mild cognitive impairment and/or mild Alzheimer's disease, comprising:
- measuring the amount or concentration of a biomolecule in a biological sample from a test subject, wherein the biomolecule is a protein (biomolecule (a1)), and wherein the biomolecule (a1) is FGF-19.
-9. (canceled)
-22. (canceled)
A method for determining the progress state of the pathological condition of mild cognitive impairment and/or mild Alzheimer's disease, comprising:
- measuring the amount or concentration of a biomolecule in a biological sample from a test subject, wherein the biomolecule is a protein (biomolecule (a1)), and wherein the biomolecule (a1) is FGF-19.
-28. (canceled)
-39. (canceled)
A kit for detection or diagnosis of mild cognitive impairment and/or mild Alzheimer's disease, comprising a means of quantifying proteins (biomolecule (a1)) selected from the group consisting of FGF-19, PLA2G10 and CPA2 and/or a triglyceride (biomolecule (b1)) free of fatty acid containing two or more unsaturated bonds, in a biological sample from a test subject.
(canceled)
Dependencies are inferred from the claim text.